Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215786 | 0.91 | CYP3A4 (0.51) | MAPK14MAPK11CYP3A4CYP2C9KIT | |
| SCHEMBL2216809 | 0.90 | CYP3A4 (0.52) | MAPK14MAPK11CYP3A4CYP2C9KIT | |
| SCHEMBL2213705 | 0.90 | MAPK14 (0.52) | MAPK14MAPK11CYP3A4CYP2C9KIT | |
| SCHEMBL2215591 | 0.88 | MAPK14 (0.48) | MAPK14MAPK11CYP3A4CYP2C9RIPK2 | |
| SCHEMBL2212193 | 0.86 | MAPK14 (0.44) | MAPK14MAPK11CYP3A4CYP2C9RIPK2 | |
| SCHEMBL1383587 | 0.86 | MAPK14 (0.56) | MAPK14MAPK11CYP3A4CYP2C9TAS1R3 | |
| SCHEMBL2214411 | 0.84 | MAPK14 (0.46) | MAPK14MAPK11CYP3A4CYP2C9RIPK2 | |
| SCHEMBL2214258 | 0.84 | CYP3A4 (0.46) | MAPK14MAPK11CYP3A4CYP2C9KIT | |
| SCHEMBL2216452 | 0.84 | MAPK14 (0.51) | MAPK14MAPK11CYP3A4CYP2C9KIT | |
| SCHEMBL2218133 | 0.82 | MAPK14 (0.54) | MAPK14MAPK11KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641764-B1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |